This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.
1. Postmenopausal women aged 50-90 years
2. BMD T-score ≤ -3.0 at any lumbar vertebra
3. Physically and mentally capable of understanding and complying with the study protocol and follow-up
4. Signed informed consent
1. Previous osteoporosis treatment within the past two years, including Romosozumab, Teriparatide, Denosumab, Alendronate, Ibandronate, Zoledronic Acid, Risedronate, Raloxifene, or Bazedoxifene
2. Allergy to Romosozumab or Denosumab
3. Secondary osteoporosis
4. Autoimmune disease